Owing to a Publisher error Declaration/Conflict of Interest statements were not included in the published versions of the following articles, that appeared in previous issues of Respiratory Investigation.
The appropriate Declaration/Conflict of Interest statements, provided by the Authors, are included below.
-
1.
“Our obligation to find treatable and untreatable traits in patients with chronic airway diseases” (Respiratory Investigation, 2019; 57: 293–294) https://doi.org/10.1016/j.resinv.2019.03.003
Declaration of interest: The author declares no conflict of interest.
-
2.
“Serum amyloid A in patients with idiopathic pulmonary fibrosis” (Respiratory Investigation, 2019; 57: 430–434) https://doi.org/10.1016/j.resinv.2019.03.010
Declaration of interest: The author declares no conflict of interest.
-
3.
“Mesalazine-induced airway obstruction: Utility of pulmonary function testing in drug-induced lung diseases” (Respiratory Investigation, 2019; 57: 611–614) https://doi.org/10.1016/j.resinv.2019.09.002
Declaration of interest: The author declares no conflict of interest.
-
4.
“The role of molecular diagnosis in acute respiratory tract infection” (Respiratory Investigation, 2019; 57: 511) https://doi.org/10.1016/j.resinv.2019.06.007
Declaration of interest: The author declares no conflict of interest.
-
5.
“Immune reconstitution inflammatory syndrome in the lung in non-human immunodeficiency virus patients” (Respiratory Investigation, 2020; 58: 36–44) https://doi.org/10.1016/j.resinv.2019.11.001
Declaration of interest: The author declares no conflict of interest.
-
6.
“Introducing the new anti-influenza drug, baloxavir marboxil” (Respiratory Investigation, 2020; 58: 1–3) https://doi.org/10.1016/j.resinv.2019.10.005
Declaration of interest: The author received lecture fees from SHIONOGI COMPANY, LIMITED and DAIICHI SANKYO COMPANY, LIMITED.
-
7.
“Usefulness of new diagnostic criteria for chronic hypersensitivity pneumonitis established on the basis of a Delphi survey: A Japanese cohort study” (Respiratory Investigation, 2020; 58: 52–58) https://doi.org/10.1016/j.resinv.2019.10.001
Declaration of interest: Dr Kondoh reports advisory board fees and personal fees from Asahi Kasei Pharma Corp., personal fees from Boehringer Ingelheim Co., Ltd., personal fees from Eisai Inc., personal fees from Kyorin Pharmaceutical Co., Ltd., personal fees from Novartis Pharma K.K., personal fees from Shionogi & Co., Ltd., and personal fees from Teijin Pharma Limited, all unassociated with the present work. The other authors have no conflict of interest.
-
8.
“Should pulmonologists be gatekeepers or supporters for preoperative patients?” (Respiratory Investigation, 2020; 58: 4–6) https://doi.org/10.1016/j.resinv.2019.09.001
Declaration of interest: Toshiaki Kikuchi received a research grant from AstraZeneca; Toshiaki Kikuchi received lecture fees from Pfizer Japan Inc., DAIICHI SANKYO Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca; Toshiaki Kikuchi received a research donation from Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Boehringer Ingelheim Co., Ltd.; Satoshi Hokari has no conflict of interest.
-
9.
“Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation” (Respiratory Investigation, 2020; 58: 45–51) https://doi.org/10.1016/j.resinv.2019.08.004
Declaration of interest: Ji Hyun Kim is an employee of Janssen Korea Ltd. Tae Sun Shim, O Jung Kwon, Youngsam Kim, Moo Suk Park, and Sungchul Hwang declare no conflict of interest.
10. “Clinical staging of idiopathic pulmonary fibrosis” (Respiratory Investigation, 2020; 58: 81–82) https://doi.org/10.1016/j.resinv.2019.12.001
Declaration of interest: The author declares no conflict of interest.
11. “The release of phosphorylated-HSP27 from activated platelets of obstructive sleep apnea syndrome (OSAS) patients” (Respiratory Investigation, 2020; 58: 117–127) https://doi.org/10.1016/j.resinv.2019.10.006
Declaration of interest: The author declares no conflict of interest.
12. “Approach to management of chronic cough and chronic airway diseases: “Treatable traits” or correct diagnosis?” (Respiratory Investigation, 2020; 58: 129–130) https://doi.org/10.1016/j.resinv.2020.02.002
Declaration of interest: The author declares no conflict of interest.